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Abstract
Objective
To evaluate improvement in survival of lymphoma patients from 1990 to 2014, stratified by
age, sex and race using Surveillance Epidemiology and End-Result Survey Program
(SEER) data.
Study design and setting
We identified 113,788 incident lymphoma cases from nine SEER cancer registries were fol-
lowed up for cause-specific mortality from lymphoma. Cox proportional hazard regression
was used to estimate hazard ratios (HRs) and their respective 95% confidence interval (CIs)
for various time periods within groups stratified by race, age and sex.
Results
Five-year survival for Hodgkin’s lymphoma (HL) was 89% for patients 20–49 years of
age. For this age group, compared to 1990–1994, survival significantly improved in
2000–2004 (HR = 0.65; 95% CI: 0.54–0.78), 2005–2009 (HR = 0.46, 95% CI: 0.38–0.57)
and 2010–2014 (HR = 0.29, 95% CI: 0.20–0.41). Hodgkin’s lymphoma patients aged
75–85 years had 5-year survival of 37% and in these patients, compared to 1990-1994,
survival only improved from 2005 onward (HR = 0.67, 95% CI: 0.50–0.90). In patients
with non-Hodgkin’s Lymphoma (NHL), all age groups showed survival improvements
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between 1990–1994 period and 2010–2014 period. Improvements in HL and NHL sur-
vival were seen for all race categories and both genders.
Conclusion
Survival among US lymphoma patients has improved substantially between 1990–1994
period and 2010–2014 period, though disease-specific mortality was still higher in older age
groups.
Introduction
Survival of patients with lymphoma has substantially improved over the last few decades due
to advances in therapy, particularly approaches that target pathways of malignancy and lead to
partial or complete recovery [1,2]. Non-Hodgkin’s Lymphoma (NHL), the more prevalent
form of the two major types of lymphoma, has a 5-year survival of 70%, while Hodgkin’s lym-
phoma (HL) has a 5-year survival of 86% [3]. Advances in HIV/AIDS treatment has also led to
reduced incidence of HL and NHL [4,5].
Prevailing incidence rates and survival of lymphoma vary by race, sex and age. For example,
NHL is more common in adults aged 65–74, and patients aged 75 to 84 have the highest mor-
tality [3]. Some studies have found no significant differences in survival between men and
women [6,7] while others suggest that females have better survival than males [8–10]. Regard-
ing to race, white males and white females have the highest age-adjusted incidence rates and
mortality [3].
Also, differences in access to advanced therapy and in participation in clinical trials for new
therapies have been found in several studies [11–14]. Specifically, blacks, females and elderly
patients are less likely to participate in clinical trials and less likely to have access to better treat-
ment modalities [14,15]. For example, Shavers et al. [12] found that racial disparity still per-
sisted with respect to access to quality care, cancer diagnostic services and service delivery.
Another study by Tao et al. [11] also showed that low socio-economic status and lack of ade-
quate health insurance coverage were associated with poorer survival of lymphoma patients.
These studies suggest that even though survival has generally improved over time, improve-
ment may not necessarily be the same for all patients. While substantial efforts have been
made to determine survival and its predictors of lymphoma, there is a limited understanding
the secular trends in survival of lymphoma patients. To address this gap, we examined lym-
phoma patient survival by age, sex and race across 25-year span using SEER data during 1990–
2014 period and explored possible reasons for such differences.
Materials and methods
We obtained data from the National Cancer Institute’s cancer registry program, the Surveil-
lance Epidemiologic and End-Result Survey (SEER) [3]. Accordingly, the SEER data are col-
lected from 18 cancer registries and represent 28% of the US population. SEER data contain
cancer incidence and mortality information, as well as individual patient demographics and
clinical characteristics including cancer staging, grade and treatment. Data from nine cancer
registries in the SEER program was used for the current analysis, including Atlanta, Georgia;
Connecticut; Detroit, Michigan; Hawaii; Iowa; New Mexico; San Francisco-Oakland, Califor-
nia; Seattle-Puget Sound, Washington; and Utah.
Survival disparities for lymphoma
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We identified patients with first primary diagnoses of lymphoma from 1990 to 2014 (97,300
cases of NHL and 16,488 cases of HL) comprising of the following ICD-0-3 codes: 9590–91
9596–97, 9650–55, 9659, 9661–67, 9670–71, 9673, 9675, 9678–80, 9684, 9687–91, 9695, 9698–
9705, 9708–09, 9712, 9714, 9716–19, 9726–29, 9735, 9737–38, 9811–12, 9816, 9818, 9823, 9827
and 9837. Patients less than 20 years of age or older than 85 years, patients with unknown age
and those whose diagnosis was only based on autopsy report or based on death certificate were
excluded. Other information that was obtained included age at diagnosis, sex, marital status,
race and ethnicity, grade staging based on Ann Arbor classification, and SEER registry loca-
tion. The SEER race data comprised 5 categories: White, African American, American Indian/
Alaskan Native, Asian/Pacific Islander, and unknown. Because the number of American
Indian/Alaskan Native patients was small, they were combined with “unknown” into a single
group as “other”. Age at diagnosis was categorized into: 20–49, 50–64, 65–74 and 75–84 years.
Marital status was recoded such that small sized categories including divorced, widowed,
domestic partner and separated were grouped as “other”. Ann Arbor classification for staging
included categories: 1) stage I disease involving a single lymph node; 2) stage II disease involv-
ing two or more lymph nodes on the same side of the diaphragm; 3) stage III disease involving
lymph nodes on both sides of the diaphragm; and 4) stage IV disseminated disease.
The primary outcome was SEER-identified disease-specific mortality from lymphoma. Sur-
vival time was defined from date of diagnosis to date last known to be alive, date of death or at
December 31, 2014. Patients still alive on December 31, 2014, or who had died of other causes
were censored at date of death. For the baseline period 1990 to 1994, cancer-specific survival
was estimated using Kaplan-Meier (product-limit) survival tables at 1, 3, and 5 years according
to categories of age, sex, and race. We used Cox proportional hazards regression to calculate
Hazard Ratios (HRs) and their 95% confidence intervals (CIs) for cancer specific mortality for
patients diagnosed during 1995 to 1999, 2000 to 2004, 2005 to 2009, and 2010 to 2014 periods
and compared with those diagnosed at the baseline (1990 to 1994 period) for each sex, race
and age group. Interaction between year of diagnosis with age, sex and race was evaluated
using likelihood ratio test [16,17]. We also calculated HRs and 95% CIs for each 5-year incre-
ment from 1990 to 2014 within each stage of cancer and age group of patients (i.e., 3-way inter-
action between year of diagnosis, stage and age group). Variables included in the final models
were age, race, sex, marital status, stage and SEER registry site. The proportional hazard
assumption was evaluated using Schoenfeld residual plots and log-log survival plots for each
variable that were evaluated in the current analysis. Because individuals diagnosed in the later
years of follow up with lymphoma may not have had enough follow up time to die as a result
of their disease, we performed a sensitivity analysis by excluding cases diagnosed from 2010 to
2014 and repeating the survival analysis. We compared the results of both analyses to see if
there were differences in the overall conclusion. All statistical analyses were performed using
SAS 9.4 (SAS Institute Inc., Cary, NC) and SEERstat 8.3.2. All reported P-values were two-
sided and the threshold 0.05 was considered a significant level.
Results
We identified a total of 133,788 eligible lymphoma patients, diagnosed from 1990 to 2014.
During the period of 1990–1994, survival rates were lowest for African—American patients in
both HL (5-year survival: 73%) and NHL (40%). Men had poorer survival for lymphoma in
general (5-year survival: 48%), HL (80%) and NHL (42%). Survival was lowest for the oldest
age group (75–85) while those 50–64 years had the best overall survival for NHL and those
aged 20–49 years had the best survival for HL (Table 1).
Survival disparities for lymphoma
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Survival improvement differed by race over time from 1995 to 2014 (Table 2 and Fig 1).
Whites had significant improvement in survival for both HL and NHL (Table 2 and Fig
1B–1C). For HL, there has been no improvement in survival for Asian Americans from 1995
to 2014. In African Americans with HL, survival increased significantly during 1995–1999
period, compared to 1990–1994 period. However, compared to 1995–1999 period, there has
been no significant difference in survival in all the time periods from 2000 to 2014 (Fig 1B).
Table 1. Cancer-specific survival (Percentage) for lymphoma patients by age group, race/ethnicity, and sex diagnosed in 9 SEER registries (1990–1994).
Survival time Age Race Sex
20–49 50–64 65–74 75–85 White African
American
Asian Other Men Women
Lymphoma
1 year 74.30 78.28 72.61 63.79 73.75 66.10 69.48 82.94 68.99 78.08
3 years 64.74 63.77 57.03 46.27 60.54 51.41 56.11 71.91 54.78 65.83
5 years 61.62 56.21 48.34 37.93 54.19 46.56 50.26 70.02 48.67 59.53
Hodgkin Lymphoma
1 year 97.00 89.47 74.61 67.57 93.28 89.03 85.58 100 92.49 92.97
3 years 91.34 80.14 60.40 44.35 85.99 79.19 81.94 92.31 83.94 86.87
5 years 88.86 72.52 52.70 36.72 82.65 73.25 78.22 92.31 80.02 83.69
Non-Hodgkin Lymphoma
1 year 64.12 77.41 72.51 63.61 70.24 60.83 68.13 80.64 64.47 73.00
3 years 52.80 62.52 56.86 46.36 55.92 44.98 53.99 69.24 49.21 59.26
5 years 49.37 54.97 48.12 37.99 48.97 40.36 47.95 67.11 42.73 52.57
https://doi.org/10.1371/journal.pone.0199745.t001
Table 2. Multivariate-Adjusted Hazard Ratios (HRs) and 95% CIs for cancer-specific death (due to lymphoma) by race and year of diagnosis in 9 SEER Registries
(1990–2014).
Race Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma
HR (95% CI) HR (95% CI) HR (95% CI)
White
1990–1994 Ref Ref Ref
1995–1999 0.82 (0.80–0.85) 0.89 (0.78–1.01) 0.82 (0.79–0.84)
2000–2004 0.56 (0.54–0.58) 0.71 (0.62–0.82) 0.54 (0.52–0.56)
2005–2009 0.42 (0.40–0.43) 0.50 (0.43–0.58) 0.41 (0.39–0.43)
2010–2014 0.36 (0.34–0.38) 0.39 (0.32–0.48) 0.35 (0.34–0.37)
Asian
1990–1994 Ref Ref Ref
1995–1999 0.83 (0.73–0.94) 0.73 (0.37–1.43) 0.84 (0.74–0.95)
2000–2004 0.64 (0.56–0.72) 0.75 (0.42–1.34) 0.64 (0.57–0.73)
2005–2009 0.49 (0.43–0.56) 0.71 (0.38–1.31) 0.50 (0.44–0.57)
2010–2014 0.50 (0.44–0.58) 0.54 (0.27–1.10) 0.51 (0.45–0.59)
African American
1990–1994 Ref Ref Ref
1995–1999 0.77 (0.71–0.85) 0.70 (0.50–0.96) 0.76 (0.68–0.84)
2000–2004 0.55 (0.50–0.61) 0.68 (0.50–0.92) 0.52 (0.47–0.58)
2005–2009 0.45 (0.41–0.50) 0.39 (0.28–0.55) 0.45 (0.40–0.52)
2010–2014 0.38 (0.34–0.43) 0.34 (0.22–0.52) 0.38 (0.33–0.43)
CI: confidence interval; HR: Hazard ratio
https://doi.org/10.1371/journal.pone.0199745.t002
Survival disparities for lymphoma
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For NHL, survival improved for both whites and African Americans. In Asian American, sur-
vival improved over the entire study period. However, survival from 2010 to 2014 was not sig-
nificantly different from that in 2005–2009 period (Fig 1C).
Table 3 evaluated the cancer-specific death by age group and year of diagnosis. We
observed an improvement in survival across age groups for all patients with lymphoma. Those
with younger age had higher improvement in survival (Table 3 and Fig 2A). For example, com-
pared to 1990–1994 period, the hazard ratio in 2010–2014 period for those aged 20–49 was
0.27 (95% CI: 0.24–0.30) while it was 0.55 (95% CI: 0.51–0.59) for those 75–85 years old. For
HL, survival began to significantly improve for the younger age groups much earlier compared
to the older age groups (Table 3 and Fig 2B). For those aged 20–49, 50–64, and 65–74, survival
during 2000–2004 period was significantly better compared to survival among these age group
during 1990–1994 period (HR = 0.65, 95% CI: 0.54–0.78; 0.60, (0.45–0.80) and 0.72, (0.53–
0.97); respectively). In those who were older than 75 years of age, survival appeared to signifi-
cantly improve only during 2005–2009 period (HR = 0.67, 95% CI: 0.50–0.90; reference group:
1990–1994 period). For NHL, survival began to significantly improve during 1995–1999
period for all ages except those older than 75 years where survival started to improve in 2000–
2004 period (HR = 0.75, 95% CI: 0.71–0.80) (Table 3 and Fig 2C).
Table 4 shown the 3-way interaction between stage, age and year of diagnosis with survival
of lymphoma, HL and NHL patients. For HL, the improvement in survival across all the stages
were more pronounced in the younger age groups compared to the older age groups. How-
ever, patients at 65–74 year of age with stage IV HL disease had the most favorable survival
(HR = 0.79, 95% CI: 0.69–0.91) (Table 4 and Fig 3B). There was, however, no significant statis-
tical difference in survival for all age groups within each stage (Fig 3B). For NHL, younger
aged individuals had the most favorable survival in all four stages of the disease (Fig 3C). Sur-
vival was decreased with advancing stage and within each stage, with advancing age (Fig 3C).
Sensitivity analysis that excluded cases diagnosed from 2010 to 2014 showed no material dif-
ference in survival trend for the different stages of the disease (S1 Table). Indeed, younger age
patients in each stage had the most favorable survival except for stage IV where adults aged 65
Fig 1. Forest plots showing Multivariate-Adjusted Hazard Ratios (HRs) and 95%CIs for cancer-specific death (due to lymphoma) by race and year of
Diagnosis in 9 SEER Registries (1990–2014). HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma; HR: Hazard ratio.
https://doi.org/10.1371/journal.pone.0199745.g001
Survival disparities for lymphoma
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to 74 had the most favorable survival (HR = 0.76, 95% CI: 0.64–0.90). For NHL, improvement
in survival over time occurred in all age groups for all stages but much greater in the younger
patients compared to the older patients.
Discussion
Using data from SEER, we found slower improvement in survival among older patients com-
pared to younger patients for all lymphomas combined and for HL and NHL separately during
the past 20 years in the United States. The age-related disparity in survival was most striking
for NHL, for which the bigger advances in treatment were made within the study period. Nota-
bly, improved survival was highest within the period 1995 to 2004 when immunotherapy
(Rituximab) was introduced to treat certain types of NHL and was commonly used later [18].
This period also corresponded to the widespread use of combination antiretroviral therapy to
treat HIV/AIDS [19], which was associated with risk of poor prognosis for NHL [20].
While there is no comparable study to ours, this pattern is similar to findings from a recent
study by Zeng et al. [21] in which they found that age-related gap in survival to be wider for
prostate, colorectal and breast cancers, owing to the highest treatment advances among the
cancers examined. Moreover, analysis based on lymphoma stage was suggestive of better
improved survival among younger patients for more localized than for advanced NHL and, to
Table 3. Multivariate-Adjusted Hazard Ratios (HRs) and 95%CIs for cancer-specific death (due to lymphoma), by age group and year of diagnosis in Nine SEER
Registries During 1990–2014 Period.
Age Group and Period Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma
HR (95% CI) HR (95% CI) HR (95% CI)
20–49
1990–1994 Ref. Ref. Ref.
1995–1999 0.71 (0.67–0.75) 0.85 (0.71–1.01) 0.67 (0.63–0.71)
2000–2004 0.43 (0.41–0.47) 0.65 (0.54–0.78) 0.39 (0.36–0.42)
2005–2009 0.32 (0.29–0.34) 0.46 (0.38–0.57) 0.29 (0.26–0.31)
2010–2014 0.27 (0.24–0.30) 0.29 (0.20–0.40) 0.26 (0.23–0.29)
50–64
1990–1994 Ref. Ref. Ref.
1995–1999 0.75 (0.71–0.80) 0.74 (0.55–0.98) 0.75 (0.71–0.80)
2000–2004 0.47 (0.44–0.50) 0.60 (0.45–0.80) 0.47 (0.44–0.50)
2005–2009 0.35 (0.33–0.38) 0.35 (0.26–0.48) 0.35 (0.33 0.38)
2010–2014 0.32 (0.29–0.34) 0.42 (0.29–0.59) 0.31 (0.29 0.34)
65–74
1990–1994 Ref. Ref. Ref.
1995–1999 0.89 (0.84–0.95) 0.98 (0.72–1.32) 0.89 (0.84–0.94)
2000–2004 0.59 (0.56–0.63) 0.72 (0.53–0.97) 0.59 (0.55–0.63)
2005–2009 0.43 (0.40–0.46) 0.54 (0.40–0.74) 0.43 (0.40–0.46)
2010–2014 0.35 (0.32–0.38) 0.37 (0.25–0.57) 0.35 (0.32–0.38)
75–84
1990–1994 Ref. Ref. Ref.
1995–1999 0.95 (0.90–1.01) 0.89 (0.66–1.19) 0.96 (0.90–1.02)
2000–2004 0.76 (0.72–0.81) 1.05 (0.78–1.40) 0.75 (0.71–0.80)
2005–2009 0.61 (0.58–0.65) 0.67 (0.50–0.90) 0.61 (0.57–0.65)
2010–2014 0.55 (0.51–0.59) 0.54 (0.38–0.77) 0.55 (0.51–0.60)
CI: confidence interval; HR: Hazard ratio
https://doi.org/10.1371/journal.pone.0199745.t003
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Fig 2. Forest plots showing Multivariate-Adjusted Hazard Ratios (HRs) and 95%CIs for Cancer-Specific Death (due to lymphoma), by Age Group and Year
of Diagnosis in 9 SEER Registries (1990–2014). HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma; HR: Hazard ratio.
https://doi.org/10.1371/journal.pone.0199745.g002
Table 4. Multivariate-Adjusted Hazard Ratios (HRs) and 95% CIs for cancer-specific death (due to lymphoma) by stage and age group in Nine SEER Registries dur-
ing 1990–2014 period.
Age Group and Period Lymphoma Hodgkin Lymphoma Non-Hodgkin Lymphoma
HR (95% CI) HR (95% CI) HR (95% CI)
Stage 1
20–49 0.59 (0.56–0.61) 0.69 (0.57–0.82) 0.56 (0.53–0.59)
50–64 0.69 (0.66–0.71) 0.81 (0.65–1.00) 0.68 (0.65–0.71)
65–74 0.72 (0.69–0.75) 0.76 (0.63–0.92) 0.72 (0.69–0.75)
75–85 0.85 (0.82–0.88) 0.98 (0.82–1.17) 0.84 (0.81–0.87)
Stage 2
20–49 0.70 (0.67–0.74) 0.69 (0.62–0.76) 0.68 (0.64–0.72)
50–64 0.68 (0.65–0.72) 0.64 (0.54–0.76) 0.68 (0.65–0.72)
65–74 0.76 (0.73–0.80) 0.72 (0.59–0.87) 0.77 (0.73–0.80)
75–85 0.85 (0.82–0.89) 0.82 (0.69–0.97) 0.85 (0.82–0.89)
Stage 3
20–49 0.78 (0.74–0.82) 0.86 (0.77–0.96) 0.72 (0.68–0.76)
50–64 0.70 (0.67–0.73) 0.75 (0.65–0.87) 0.69 (0.66–0.72)
65–74 0.76 (0.73–0.80) 0.86 (0.74–0.99) 0.73 (0.70–0.77)
75–85 0.79 (0.77–0.82) 0.79 (0.68–0.92) 0.80 (0.76–0.83)
20–49
Stage 4
20–49 0.71 ((0.69–0.73) 0.78 (0.72–0.85) 0.71 (0.69–0.73)
50–64 0.74 (0.72–0.76) 0.81 (0.71–0.91) 0.74 (0.72–0.76)
65–74 0.77 (0.75–0.79) 0.79 (0.69–0.91) 0.77 (0.75–0.79)
75–85 0.84 (0.82–0.86) 0.90 (0.80–1.01) 0.84 (0.82–0.86)
CI: confidence interval; HR: Hazard ratio
https://doi.org/10.1371/journal.pone.0199745.t004
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a lesser extent, HL. Findings from clinical trials and other studies also showed improved NHL
survival for patients with more localized disease associated with more advanced surgical tech-
niques and adjuvant chemotherapy [22,23]. These results suggested that the age-related dispar-
ity in lymphoma survival may due to different utilization of more recent cancer treatments
among the elderly.
From available evidence, older age is associated with higher rate of complications from sur-
gery and toxicity from chemotherapy and radiotherapy [24–26]. In addition, there is prepon-
derance of other factors that could affect the outcome of cancer treatment among the elderly,
such as impaired organ function, comorbidity and malnutrition [27–29]. These may have led
physicians to use less aggressive or shortened treatment courses in order to minimize harm to
the elderly patients [30]. Additionally, limited participation of elderly cancer patients in clini-
cal trials [15] has resulted in general dearth of information on how they will react to combina-
tion chemotherapy or (newer) targeted cancer treatments [31,32]. A classic dogma is that
treatments that work well for younger cancer patients may be less useful or more harmful for
older ones [33]. However, evidence exist to suggest otherwise, at least for some types of lym-
phoma [34]. Therefore, in showing that differences in lymphoma survival improvement exist
based on age, our findings highlight the relevance of studies both observational and experi-
mental, involving the elderly, to develop the most proper cancer treatments and to understand
the side effect profile among elderly population of patients.
We found differences in survival improvement based on race, with Asians having the lowest
rise in survival during the whole study period, especially for HL in which none of the 5-year
intervals had a statistically significant increase in survival among Asians. Previous studies also
reported similar racial pattern of survival for lymphomas, with whites and African Americans
having more favorable survival than Asians [35–37]. However, another study on racial dispar-
ity in HL survival found Asians to have better survival compared to African Americans [38].
Remarkably, we found African Americans to have better HL survival advancement compared
to whites. This is consistent with results from previous studies which showed reduced survival
gap between whites and African Americans from 2000 to 2009 for follicular lymphoma [37].
Although previous studies have found females to have better survival for all non-gender
dependent malignancies [39] and some types of lymphomas [40], we did not find any differ-
ence in survival improvement across the years between males and females in our analysis.
Fig 3. Forest plots showing Multivariate-Adjusted Hazard Ratios (HRs) and 95% CIs for cancer-specific death (due to lymphoma) by stage and age group in
9 SEER Registries (1990–2014). HL: Hodgkin’s Lymphoma; NHL: Non-Hodgkin’s Lymphoma; HR: Hazard ratio.
https://doi.org/10.1371/journal.pone.0199745.g003
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The current analysis has some limitations. First, because we only focused on analysis on
those who were 20 years or older, we could not generalize our finding to young patients (i.e.,
less than 20 years of age). Ability to apply our results to the general US population could also
be limited by the SEER program’s over sampling of foreign born and urban dwelling individu-
als. However, our data closely resembled the general US population in terms of key sociode-
mographic characteristics within the age range of participants we considered in our study.
Second, we could not obtain information from the SEER registries to assess whether cancer
screening and diagnosis had any influence on the results from our analysis. Lead-time bias
could have occurred if screening trends were different over time between the groups we com-
pared. However, we could not find any evidence to suggest screening trend differed over the
period. Also, the fact that we observed disparity in improvement in survival due to age across
almost all stages of lymphoma means the disparities could not have been only due to changes
in screening practices within the study period. Other limitations include lack of information in
the SEER database on many factors with potential to affect lymphoma survival. This unmea-
sured confounding could occur, for example, due to HIV/AIDS and other comorbidities, life
style factors, socioeconomic status, health insurance coverage of the individual, among other
factors. Other limitations include those that are known to occur in studies involving retrospec-
tive analysis of databases such as the SEER. Because of the possibility that some cases diag-
nosed in the interval 2010 to 2014 may not have had up to five-year follow up, we carried out
sensitivity analysis by excluding this time interval from the analysis. However, results from
these sensitivity analyses shown no material changes from current analysis.
Despite the limitations, our study has strength in many areas. To our knowledge, this is the
first effort to evaluate the secular trend in survival of lymphoma patients by age, sex, and race/
ethnicity groups with a largest sample size to date. Also, barring the few limitations noted ear-
lier, the sample used is representative of the US population and findings can be generalizable.
Moreover, stringent measures were taken by the SEER to ensure production of data of high
quality that is reliable.
The disparities we have observed in survival improvement among lymphoma patients
based on age and race may be indicating divergent levels of cancer care and/or response to
treatment across categories of these variables. Therefore, while the better acknowledged causes
of racial disparity are being addressed to eliminate disparity in lymphoma survival, others
need to also be considered. For example, inclusion of older cancer patients and those from
minority racial groups in clinical trials should be increased so that enough evidence could be
obtained on them regarding new treatments. This may encourage clinicians to consider such
treatments in these patients to ensure they are at par with others in access to all forms of treat-
ment. Future research should focus on identifying other factors that could be responsible for
disparity in lymphoma survival.
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